MGTA-117
Conditioning for AML/MDS transplant
Phase 1/2Discontinued (Aug 2023)
Key Facts
Indication
Conditioning for AML/MDS transplant
Phase
Phase 1/2
Status
Discontinued (Aug 2023)
Company
About Magenta Therapeutics
Magenta Therapeutics aimed to transform stem cell transplantation by developing a suite of targeted therapies to replace toxic conditioning regimens, improve stem cell collection, and accelerate immune recovery. Its strategy addressed significant unmet needs in autoimmune diseases, blood cancers, and genetic disorders like sickle cell disease. However, following disappointing Phase 2 clinical trial results in mid-2023, the company discontinued its programs, explored strategic alternatives, and its assets were ultimately acquired by Dianthus Therapeutics in October 2023, effectively ending its independent operations.
View full company profile